The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Deborah L. White

Haematology Department

Centre for Cancer Biology

SA Pathology (IMVS Campus)

University of Adelaide

Australia

[email]@imvs.sa.gov.au

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Haematology Department, Centre for Cancer Biology, SA Pathology (IMVS Campus), University of Adelaide, Australia. 2010
  • Division of Haematology, SA Pathology IMVS/RAH Campus, Frome Road, Adelaide, Australia. 2009
  • Division of Hematology, Institute of Medical and Veterinary Science, Adelaide, Australia. 2005 - 2007

References

  1. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. White, D.L., Dang, P., Engler, J., Frede, A., Zrim, S., Osborn, M., Saunders, V.A., Manley, P.W., Hughes, T.P. J. Clin. Oncol. (2010) [Pubmed]
  2. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. White, D.L., Hughes, T.P. Curr. Hematol. Malig. Rep (2009) [Pubmed]
  3. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. White, D., Saunders, V., Grigg, A., Arthur, C., Filshie, R., Leahy, M.F., Lynch, K., To, L.B., Hughes, T. J. Clin. Oncol. (2007) [Pubmed]
  4. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. White, D.L., Saunders, V.A., Dang, P., Engler, J., Venables, A., Zrim, S., Zannettino, A., Lynch, K., Manley, P.W., Hughes, T. Blood (2007) [Pubmed]
  5. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. White, D.L., Saunders, V.A., Dang, P., Engler, J., Zannettino, A.C., Cambareri, A.C., Quinn, S.R., Manley, P.W., Hughes, T.P. Blood (2006) [Pubmed]
  6. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. White, D., Saunders, V., Lyons, A.B., Branford, S., Grigg, A., To, L.B., Hughes, T. Blood (2005) [Pubmed]
 
WikiGenes - Universities